Calixar has announced the completion of its second round of financing with its historical investors - Siparex, Veymont Participations, INPG Entreprise SA, and regional business angels (Health-Angels Rhône-Alpes, Savoie Angels and Grenoble Angels).
Moreover, Bpifrance (French public investment bank) and the Banque Populaire supplemented this funding through repayable advance and specific credit (Innov & Plus) supported by the European Union.
The new financing will enable Calixar to confirm its excellent results, especially on the development of new Influenza vaccines and high affinity antibodies to GPCRs; they will be available for partnership with the pharmaceutical industry by the second semester 2015.
Calixar unique approach allows to preserve the native state of membrane proteins - 70% of therapeutic targets - involved in numerous pathologies. The company currently owns 5 patents.
“We are very proud of the continued confidence of our historical investors and financial partners. These funds will enable us to accelerate our internal research programs while continuing to offer our know-how and technologies to support our clients’ discovery programs in Europe, the United States and Japan”, declared Emmanuel Dejean, President & CEO of Calixar.
“Considering the good results obtained with global pharmaceuticals leaders as well as the recent encouraging breakthroughs on internal programs, we have decided to renew our support to Calixar to achieve this new stage of development” explained Guilhem De Vregille, Associate Director of Siparex Venture Capital.